Investigating how cyclin C affects neurodegenerative diseases caused by misfolded proteins
Official title: The Role of Cyclin C in mediating neurodegenerative proteinopathies
Funded at Rowan University School/osteopathic Med · NIH-11010409 · Data updated 2026-11-12
This study is looking at how a protein called cyclin C helps clean up damaged proteins in brain cells, which could help us understand and find new treatments for diseases like Alzheimer's and Parkinson's.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rowan University School/osteopathic Med NIH-funded |
| Lab location | 1 site (Stratford, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $201,250 |
| NIH project number | 5R21AG080666-02 |
| Project ID | NIH-11010409 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neurodegenerative diseases such as Alzheimer's, Parkinson's, or ALS.
✕Less likely to help
Patients with neurodegenerative diseases not related to protein aggregation or those in very advanced stages may not benefit from this research.
What this research studies
This research focuses on understanding the role of cyclin C in the clearance of aggregated and misfolded proteins associated with neurodegenerative diseases like Alzheimer's and Parkinson's. By using model systems such as yeast and mammalian neurons, the study aims to explore how mitochondria contribute to the health of nerve cells and the mechanisms behind protein accumulation. The goal is to uncover the relationship between different neurodegenerative diseases and identify potential therapeutic targets for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating neurodegenerative diseases by targeting the mechanisms of protein clearance.
How similar studies have gone: Previous research has shown promising results in understanding the mechanisms of proteinopathies, indicating that this approach may yield valuable insights.
Where this research is happening
-
Rowan University School/osteopathic Med
Stratford, United States Active
Researchers
- Principal investigator: Cooper, Katrina Frances — Rowan University School/osteopathic Med
- Study coordinator: Cooper, Katrina Frances
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.